Avalon GloboCare Appoints Dr. Bo Chen as Vice President of Mergers & Acquisitions

Pharmaceutical Investing

Avalon GloboCare (OTCQB:AVCO), a leading global developer of cell-based technologies announced the Company has appointed Dr. Bo Chen as Vice President, Business Development to lead mergers & acquisitions activity. Dr. Chen will focus on executing Avalon’s acquisition strategy by helping identify companies with a strategic fit within the cell therapeutics, cell diagnostics and rehabilitation sectors. As …

Avalon GloboCare (OTCQB:AVCO), a leading global developer of cell-based technologies announced the Company has appointed Dr. Bo Chen as Vice President, Business Development to lead mergers & acquisitions activity. Dr. Chen will focus on executing Avalon’s acquisition strategy by helping identify companies with a strategic fit within the cell therapeutics, cell diagnostics and rehabilitation sectors.
As quoted in the press release:

Dr. Bo Chen was one of the original founders of the Ludaopei Hospital Group in China, and has served as the global business development director for the past 5 years. The Ludaopei Hospital Group is one of the fastest growing private medical companies in China presently, consisting of multiple hospitals and research centers specialized in leukemia and cell therapeutics.

Click here to read the full press release.

The Conversation (0)
×